Michael Mina - The neglected CT (Cycle Threshold) levels to determine viral load and infectiousness
Dr. Michael Mina, MD, PhD is an Assistant Professor of Epidemiology at Harvard T. H. Chan School of Public Health and a core member of the Center for Communicable Disease Dynamics (CCDD). He is additionally an Assistant Professor in Immunology and Infectious Diseases at HSPH and Associate Medical Director in Clinical Microbiology (molecular diagnostics) in the Department of Pathology at Brigham and Women’s Hospital, Harvard Medical School
He earned his MD and PhD degrees from Emory University, with doctoral work split between CDC, St. Jude Children’s Research Hospital, the Respiratory and Meningeal Pathogens Research Unit in Johannesburg, South Africa and the Emory Vaccine Center. He completed his post-doctoral work at Princeton University in Ecology and Evolutionary Biology (of infectious disease dynamics) with Prof. Bryan Grenfell and at Harvard Medical School in the Department of Genetics with Prof. Stephen Elledge. He completed his residency training in clinical pathology at Brigham and Women’s Hospital / Harvard Medical School.
Michael’s research combines mathematical and epidemiological models with high-throughput phage-display based serological laboratory investigations, including development of new technologies and statistical pipelines to better understand the population and immunological consequences and patterns underlying infectious diseases. Much of the work towards new technology development is performed in close collaboration with Steve Elledge at HMS. Major themes of his lab include (i) development of new approaches (laboratory and statistical methods) to enable extremely high-throughput serological surveillance of infectious pathogens; (ii) use of high-complexity antibody profiling and epidemiological data to understand the pathogenesis of vaccine preventable diseases, with a specific focus on measles infections and vaccines; (iii) elucidating broad unintended / heterologous effects of vaccines to alter transmission patterns of unrelated infectious pathogens – using serology and dynamical models; and (iv) understanding the life-history of infectious pathogens across ages, genders, geographies and times. In addition to his interests in infectious diseases, his research also explores more fundamental questions of immunity and immune repertoires: how they form, how they persist, how they are passed on and how they become perturbed during natural life-events.
Видео Michael Mina - The neglected CT (Cycle Threshold) levels to determine viral load and infectiousness канала Co-Immunity
He earned his MD and PhD degrees from Emory University, with doctoral work split between CDC, St. Jude Children’s Research Hospital, the Respiratory and Meningeal Pathogens Research Unit in Johannesburg, South Africa and the Emory Vaccine Center. He completed his post-doctoral work at Princeton University in Ecology and Evolutionary Biology (of infectious disease dynamics) with Prof. Bryan Grenfell and at Harvard Medical School in the Department of Genetics with Prof. Stephen Elledge. He completed his residency training in clinical pathology at Brigham and Women’s Hospital / Harvard Medical School.
Michael’s research combines mathematical and epidemiological models with high-throughput phage-display based serological laboratory investigations, including development of new technologies and statistical pipelines to better understand the population and immunological consequences and patterns underlying infectious diseases. Much of the work towards new technology development is performed in close collaboration with Steve Elledge at HMS. Major themes of his lab include (i) development of new approaches (laboratory and statistical methods) to enable extremely high-throughput serological surveillance of infectious pathogens; (ii) use of high-complexity antibody profiling and epidemiological data to understand the pathogenesis of vaccine preventable diseases, with a specific focus on measles infections and vaccines; (iii) elucidating broad unintended / heterologous effects of vaccines to alter transmission patterns of unrelated infectious pathogens – using serology and dynamical models; and (iv) understanding the life-history of infectious pathogens across ages, genders, geographies and times. In addition to his interests in infectious diseases, his research also explores more fundamental questions of immunity and immune repertoires: how they form, how they persist, how they are passed on and how they become perturbed during natural life-events.
Видео Michael Mina - The neglected CT (Cycle Threshold) levels to determine viral load and infectiousness канала Co-Immunity
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Michael Mina - The problem of PCR sensitivity: False Infectious - False negatives as False positives](https://i.ytimg.com/vi/4vvgefwKgSU/default.jpg)
![COVID 19 Antibody testing - What do I need to know?](https://i.ytimg.com/vi/OdFWogWGuDc/default.jpg)
![Michael Yeadon - “It is obvious to any biological expert that the pandemic is fundamentally over”](https://i.ytimg.com/vi/WapjYL1Wnfw/default.jpg)
![Michael Mina - Millions of people are being quarantined and contact traced for no reason](https://i.ytimg.com/vi/V-noluNNBEc/default.jpg)
![John Ioannidis - Overestimation. Risk Gradience. Wide Spread. Nosocomial Infection. Sweden. Life.](https://i.ytimg.com/vi/Uc5ZHFtcnXU/default.jpg)
![Michael Mina, MD, PhD - The Latest on COVID-19 Testing: How Do We Re-Open?](https://i.ytimg.com/vi/Ld_UdjGJB84/default.jpg)
![John Lee - Studies show that 40% to 80% of people have T-cell cross-reactivity to this coronavirus](https://i.ytimg.com/vi/JL7Cx2ScAtM/default.jpg)
![Gabriela Gomes - Herd immunity thresholds for SARS-CoV-2](https://i.ytimg.com/vi/VWjVYzvTHwM/default.jpg)
![Sunetra Gupta - Three Myths: 1 - We can keep it out](https://i.ytimg.com/vi/YwDNCeavoqY/default.jpg)
![Sunetra Gupta - Something that is becoming a scientific fact: Pre-existing resistance to COVID-19](https://i.ytimg.com/vi/ZCnTtKM6RK8/default.jpg)
![A NEW STUDY On Vitamin D](https://i.ytimg.com/vi/mxxl5I0B7bg/default.jpg)
![COVID-19 Update 18: When are patients really infectious?](https://i.ytimg.com/vi/uCIC8MwBebU/default.jpg)
![Michael Yeadon - If the false positive rate is higher than the prevalence you cannot use the assay](https://i.ytimg.com/vi/0vbB1IGDm3Y/default.jpg)
![Andrew Neil interviews Anders Tegnell - a second wave and what Sweden got right | SpectatorTV](https://i.ytimg.com/vi/6C99MtK4ogM/default.jpg)
![The Significance of Early Ct’s - Ask TaqMan #35](https://i.ytimg.com/vi/nqkNmCBik14/default.jpg)
![Herd Immunity and Effects: What if Some Don't Cooperate with COVID 19 Rapid Testing? with Dr. Mina](https://i.ytimg.com/vi/1qFtAm4lUAw/default.jpg)
![David Livermore - Lockdowns aren't the way out: "It is merely kicking the can down the road"](https://i.ytimg.com/vi/QS43P8MSx6Q/default.jpg)
![Positive PCR Test. Is It Really Positive?](https://i.ytimg.com/vi/jjx3doSskbU/default.jpg)
![Pandemic, Child cases and lowering fatality rates](https://i.ytimg.com/vi/82OV9YA-u_M/default.jpg)
![New Approaches to Covid-19: Rapid Testing, Herd Immunity, and the Role of Narrative](https://i.ytimg.com/vi/Ew2MEF4XX8w/default.jpg)